> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mirion Lifts Sales Outlook, Cuts Top Of EBITDA Range To $292 Million From $300 Million
- URL: https://www.bullished.co/mirion-lifts-sales-outlook-cuts-top-of-ebitda-range-to-292-million-from-300-million-82ed2fe1/
- Published: 2026-10-27T20:43:55.000Z
- Updated: 2026-10-28T15:35:58.000Z
- Description: Third-quarter revenue rose 24.5% to $277.8 million, and the company raised its cash flow outlook as it narrowed profit ranges.
- Author: Matteo Parrino
- Tags: Earnings, MIR, Industry: Industrials

Mirion Technologies, which makes radiation detection and monitoring products, raised its 2026 revenue growth outlook to about 24%-25% from 22%-24% but lowered the top of its adjusted EBITDA range to $292 million from $300 million, according to its [third-quarter results](https://www.sec.gov/Archives/edgar/data/0001809987/000162828026067591/a2026-10x27exhibit991.htm?ref=bullished.co) on Tuesday. Third-quarter revenue rose 24.5% to $277.8 million from $223.1 million a year earlier.

## Orders jump, margins slip

Net income was $7.8 million, or $0.03 a share, against $3.1 million, or $0.01, a year earlier. Adjusted earnings per share was flat at $0.12, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, with adjustments) rose to $64.8 million from $52.4 million. The adjusted EBITDA margin slipped to 23.3% from 23.5%.

Orders excluding the Paragon and Certrec acquisitions were $340 million, up 62% from $209 million. Including them, orders were $386 million, up 85%.

Chairman and CEO Thomas Logan said orders were "boosted by a 105% increase in nuclear power-related orders." Organic revenue, which strips out currency and acquisitions, rose 6.5%.

## Guidance moves in both directions

The company revised several 2026 targets:

- Organic revenue growth of about 7%-8%, from 5%-7%.
- Adjusted EBITDA of about $285 million-$292 million, from $285 million-$300 million.
- Adjusted free cash flow of about $170 million-$185 million, from $155 million-$175 million.
- Adjusted EPS of about $0.50-$0.54, from $0.48-$0.55.

Logan said the company was updating guidance "to reflect increased visibility to full year performance." He said he expects mid-to-high teens organic growth in the fourth quarter.

## Cash flow and the nuclear fleet

Adjusted free cash flow was $47 million in the quarter and $107 million for the first nine months, which Logan described as a doubling. He said net leverage should fall to about 2.6x by year-end.

Mirion sells to nuclear power plants, labs and defense customers, and its Medical segment sells cancer care quality assurance tools and dosimetry services. Logan said the company has a presence in over 98% of commercial nuclear plants globally, and that approximately 80% of its nuclear power-related revenue comes from reactors operating today.

Mirion hosts a conference call on Wednesday at 10:00 a.m. ET to discuss the results and the revised 2026 forecast.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Mirion Technologies, Inc. (MIR)](https://www.sec.gov/Archives/edgar/data/0001809987/000162828026067591/mir-20261027.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a2026-10x27exhibit991.htm — Mirion Technologies, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001809987/000162828026067591/a2026-10x27exhibit991.htm?ref=bullished.co) — SEC EDGAR